Revolution Medicines books $198M in first five weeks of Rasonque sales
- Rasonque, approved in late August for previously treated metastatic pancreatic cancer, generated $198M in Q3 sales, far above analyst forecasts of $19M to $100M.
- More than 5,000 patients were reached, helped by early-access conversions; management says it is too early to judge the steady-state trajectory.
- Revolution reported a $407.5M quarterly net loss and $3.7B in cash, while Phase 3 first-line trials continue to advance.
💡 Points Based on public reports
A $198M first quarter in a second-line pancreatic indication, part of it a one-time early-access conversion bump, says less about steady state than about unmet need: few drugs target RAS this directly. The real prize is first-line, where the Phase 3s and zoldonrasib sit. With $3.7B in cash, Revolution can fund that fight, and the bigger-pharma suitors will be watching.
RevMed's Rasonque shatters analyst estimates with $198M quarter ↗